About Enhancer

Enhancer ID: E_01_0543
Species: human
Position : chr14:37586703-37588703
Biosample name:
Experiment class : High+Lowthroughput
Enhancer type: Enhancer
Disease: Nothing
Pubmed ID:  29669022
Enhancer experiment: DNA binding domain (DBD),EMSA (electrophoretic mobility shift assays),Fluorescence-Activated Cell Sorting (FACS),Luciferase assay,Bioinformatics analysis,ChIP-seq,
Enhancer experiment description: Reporter assays show that FOXA1-dependent transcriptional activity declines when homodimeric binding is disrupted. In response to phosphatidylinositol-3 kinase inhibition DIV sites pre-bound by FOXA1 such as at the PVT1/MYC locus exhibit a strong increase in accessibility suggesting a role of the DIV configuration in the chromatin closed-open dynamics. Moreover, several disease-associated single nucleotide polymorphisms map to DIV elements and show allelic differences in FOXA1 homodimerization, reporter gene expression and are annotated as quantitative trait loci. This includes the rs541455835 variant at the MAPT locus encoding the Tau protein associated with Parkinson's disease. Collectively, the DIV guides chromatin engagement and regulation by FOXA1 and its perturbation could be linked to disease etiologies.

About Target gene

Target gene : MAPT,PVT1
Strong evidence: qRT-PCR,qPCR,ChIP,3C
Less strong evidence: RNA-Seq
Target gene experiment description: Reporter assays show that FOXA1-dependent transcriptional activity declines when homodimeric binding is disrupted. In response to phosphatidylinositol-3 kinase inhibition DIV sites pre-bound by FOXA1 such as at the PVT1/MYC locus exhibit a strong increase in accessibility suggesting a role of the DIV configuration in the chromatin closed-open dynamics. Moreover, several disease-associated single nucleotide polymorphisms map to DIV elements and show allelic differences in FOXA1 homodimerization, reporter gene expression and are annotated as quantitative trait loci. This includes the rs541455835 variant at the MAPT locus encoding the Tau protein associated with Parkinson's disease. Collectively, the DIV guides chromatin engagement and regulation by FOXA1 and its perturbation could be linked to disease etiologies.;Reporter assays show that FOXA1-dependent transcriptional activity declines when homodimeric binding is disrupted. In response to phosphatidylinositol-3 kinase inhibition DIV sites pre-bound by FOXA1 such as at the PVT1/MYC locus exhibit a strong increase in accessibility suggesting a role of the DIV configuration in the chromatin closed-open dynamics. Moreover, several disease-associated single nucleotide polymorphisms map to DIV elements and show allelic differences in FOXA1 homodimerization, reporter gene expression and are annotated as quantitative trait loci. This includes the rs541455835 variant at the MAPT locus encoding the Tau protein associated with Parkinson's disease. Collectively, the DIV guides chromatin engagement and regulation by FOXA1 and its perturbation could be linked to disease etiologies.;Reporter assays show that FOXA1-dependent transcriptional activity declines when homodimeric binding is disrupted. In response to phosphatidylinositol-3 kinase inhibition DIV sites pre-bound by FOXA1 such as at the PVT1/MYC locus exhibit a strong increase in accessibility suggesting a role of the DIV configuration in the chromatin closed-open dynamics. Moreover, several disease-associated single nucleotide polymorphisms map to DIV elements and show allelic differences in FOXA1 homodimerization, reporter gene expression and are annotated as quantitative trait loci. This includes the rs541455835 variant at the MAPT locus encoding the Tau protein associated with Parkinson's disease. Collectively, the DIV guides chromatin engagement and regulation by FOXA1 and its perturbation could be linked to disease etiologies.;Reporter assays show that FOXA1-dependent transcriptional activity declines when homodimeric binding is disrupted. In response to phosphatidylinositol-3 kinase inhibition DIV sites pre-bound by FOXA1 such as at the PVT1/MYC locus exhibit a strong increase in accessibility suggesting a role of the DIV configuration in the chromatin closed-open dynamics. Moreover, several disease-associated single nucleotide polymorphisms map to DIV elements and show allelic differences in FOXA1 homodimerization, reporter gene expression and are annotated as quantitative trait loci. This includes the rs541455835 variant at the MAPT locus encoding the Tau protein associated with Parkinson's disease. Collectively, the DIV guides chromatin engagement and regulation by FOXA1 and its perturbation could be linked to disease etiologies.;Reporter assays show that FOXA1-dependent transcriptional activity declines when homodimeric binding is disrupted. In response to phosphatidylinositol-3 kinase inhibition DIV sites pre-bound by FOXA1 such as at the PVT1/MYC locus exhibit a strong increase in accessibility suggesting a role of the DIV configuration in the chromatin closed-open dynamics. Moreover, several disease-associated single nucleotide polymorphisms map to DIV elements and show allelic differences in FOXA1 homodimerization, reporter gene expression and are annotated as quantitative trait loci. This includes the rs541455835 variant at the MAPT locus encoding the Tau protein associated with Parkinson's disease. Collectively, the DIV guides chromatin engagement and regulation by FOXA1 and its perturbation could be linked to disease etiologies.;Reporter assays show that FOXA1-dependent transcriptional activity declines when homodimeric binding is disrupted. In response to phosphatidylinositol-3 kinase inhibition DIV sites pre-bound by FOXA1 such as at the PVT1/MYC locus exhibit a strong increase in accessibility suggesting a role of the DIV configuration in the chromatin closed-open dynamics. Moreover, several disease-associated single nucleotide polymorphisms map to DIV elements and show allelic differences in FOXA1 homodimerization, reporter gene expression and are annotated as quantitative trait loci. This includes the rs541455835 variant at the MAPT locus encoding the Tau protein associated with Parkinson's disease. Collectively, the DIV guides chromatin engagement and regulation by FOXA1 and its perturbation could be linked to disease etiologies.

About TF

TF name : FOXA1(HNF3A,TCF3A)GATA3(HDR,HDRS)CTCF(MRD21)MYC(MRTLC,bHLHe39,c-Myc,MYC)
TF experiment: DNA binding domain (DBD),EMSA (electrophoretic mobility shift assays),Fluorescence-Activated Cell Sorting (FACS),Luciferase assay,Bioinformatics analysis,ChIP-seq,
TF experiment description: Reporter assays show that FOXA1-dependent transcriptional activity declines when homodimeric binding is disrupted. In response to phosphatidylinositol-3 kinase inhibition DIV sites pre-bound by FOXA1 such as at the PVT1/MYC locus exhibit a strong increase in accessibility suggesting a role of the DIV configuration in the chromatin closed-open dynamics. Moreover, several disease-associated single nucleotide polymorphisms map to DIV elements and show allelic differences in FOXA1 homodimerization, reporter gene expression and are annotated as quantitative trait loci. This includes the rs541455835 variant at the MAPT locus encoding the Tau protein associated with Parkinson's disease. Collectively, the DIV guides chromatin engagement and regulation by FOXA1 and its perturbation could be linked to disease etiologies.;Reporter assays show that FOXA1-dependent transcriptional activity declines when homodimeric binding is disrupted. In response to phosphatidylinositol-3 kinase inhibition DIV sites pre-bound by FOXA1 such as at the PVT1/MYC locus exhibit a strong increase in accessibility suggesting a role of the DIV configuration in the chromatin closed-open dynamics. Moreover, several disease-associated single nucleotide polymorphisms map to DIV elements and show allelic differences in FOXA1 homodimerization, reporter gene expression and are annotated as quantitative trait loci. This includes the rs541455835 variant at the MAPT locus encoding the Tau protein associated with Parkinson's disease. Collectively, the DIV guides chromatin engagement and regulation by FOXA1 and its perturbation could be linked to disease etiologies.;Reporter assays show that FOXA1-dependent transcriptional activity declines when homodimeric binding is disrupted. In response to phosphatidylinositol-3 kinase inhibition DIV sites pre-bound by FOXA1 such as at the PVT1/MYC locus exhibit a strong increase in accessibility suggesting a role of the DIV configuration in the chromatin closed-open dynamics. Moreover, several disease-associated single nucleotide polymorphisms map to DIV elements and show allelic differences in FOXA1 homodimerization, reporter gene expression and are annotated as quantitative trait loci. This includes the rs541455835 variant at the MAPT locus encoding the Tau protein associated with Parkinson's disease. Collectively, the DIV guides chromatin engagement and regulation by FOXA1 and its perturbation could be linked to disease etiologies.;Reporter assays show that FOXA1-dependent transcriptional activity declines when homodimeric binding is disrupted. In response to phosphatidylinositol-3 kinase inhibition DIV sites pre-bound by FOXA1 such as at the PVT1/MYC locus exhibit a strong increase in accessibility suggesting a role of the DIV configuration in the chromatin closed-open dynamics. Moreover, several disease-associated single nucleotide polymorphisms map to DIV elements and show allelic differences in FOXA1 homodimerization, reporter gene expression and are annotated as quantitative trait loci. This includes the rs541455835 variant at the MAPT locus encoding the Tau protein associated with Parkinson's disease. Collectively, the DIV guides chromatin engagement and regulation by FOXA1 and its perturbation could be linked to disease etiologies.;Reporter assays show that FOXA1-dependent transcriptional activity declines when homodimeric binding is disrupted. In response to phosphatidylinositol-3 kinase inhibition DIV sites pre-bound by FOXA1 such as at the PVT1/MYC locus exhibit a strong increase in accessibility suggesting a role of the DIV configuration in the chromatin closed-open dynamics. Moreover, several disease-associated single nucleotide polymorphisms map to DIV elements and show allelic differences in FOXA1 homodimerization, reporter gene expression and are annotated as quantitative trait loci. This includes the rs541455835 variant at the MAPT locus encoding the Tau protein associated with Parkinson's disease. Collectively, the DIV guides chromatin engagement and regulation by FOXA1 and its perturbation could be linked to disease etiologies.;Reporter assays show that FOXA1-dependent transcriptional activity declines when homodimeric binding is disrupted. In response to phosphatidylinositol-3 kinase inhibition DIV sites pre-bound by FOXA1 such as at the PVT1/MYC locus exhibit a strong increase in accessibility suggesting a role of the DIV configuration in the chromatin closed-open dynamics. Moreover, several disease-associated single nucleotide polymorphisms map to DIV elements and show allelic differences in FOXA1 homodimerization, reporter gene expression and are annotated as quantitative trait loci. This includes the rs541455835 variant at the MAPT locus encoding the Tau protein associated with Parkinson's disease. Collectively, the DIV guides chromatin engagement and regulation by FOXA1 and its perturbation could be linked to disease etiologies.

About Function

Enhancer function : Reporter assays show that FOXA1-dependent transcriptional activity declines when homodimeric binding is disrupted. In response to phosphatidylinositol-3 kinase inhibition DIV sites pre-bound by FOXA1 such as at the PVT1/MYC locus exhibit a strong increase in accessibility suggesting a role of the DIV configuration in the chromatin closed-open dynamics. Moreover, several disease-associated single nucleotide polymorphisms map to DIV elements and show allelic differences in FOXA1 homodimerization, reporter gene expression and are annotated as quantitative trait loci. This includes the rs541455835 variant at the MAPT locus encoding the Tau protein associated with Parkinson's disease. Collectively, the DIV guides chromatin engagement and regulation by FOXA1 and its perturbation could be linked to disease etiologies.
Enhancer function experiment: Immunohistochemical staining
Enhancer function
experiment description:
Reporter assays show that FOXA1-dependent transcriptional activity declines when homodimeric binding is disrupted. In response to phosphatidylinositol-3 kinase inhibition DIV sites pre-bound by FOXA1 such as at the PVT1/MYC locus exhibit a strong increase in accessibility suggesting a role of the DIV configuration in the chromatin closed-open dynamics. Moreover, several disease-associated single nucleotide polymorphisms map to DIV elements and show allelic differences in FOXA1 homodimerization, reporter gene expression and are annotated as quantitative trait loci. This includes the rs541455835 variant at the MAPT locus encoding the Tau protein associated with Parkinson's disease. Collectively, the DIV guides chromatin engagement and regulation by FOXA1 and its perturbation could be linked to disease etiologies.

About SNP

SNP ID: rs541455835

Upstream Pathway Annotation of TF

GeneName Pathway Name Source Gene Number
FOXA1 AndrogenReceptor netpath 167
FOXA1 Direct p53 effectors pid 141
FOXA1 FOXA1 transcription factor network pid 45
FOXA1 FOXA2 and FOXA3 transcription factor networks pid 45
FOXA1 Hs_Endoderm_Differentiation_WP2853_88152 wikipathways 62
GATA3 C-MYB transcription factor network pid 87
GATA3 Calcineurin-regulated NFAT-dependent transcription in lymphocytes pid 50
GATA3 Factors involved in megakaryocyte development and platelet production reactome 111
GATA3 Glucocorticoid receptor regulatory network pid 85
GATA3 IL27-mediated signaling events pid 26
GATA3 Notch signaling pathway pid 58
GATA3 Regulation of nuclear SMAD2/3 signaling pid 82
GATA3 Hs_Endochondral_Ossification_WP474_87977 wikipathways 43
GATA3 Hs_White_fat_cell_differentiation_WP3946_90940 wikipathways 30
CTCF Activation of anterior HOX genes in hindbrain development during early embryogenesis reactome 120
CTCF TGF_beta_Receptor netpath 220
MYC AP-1 transcription factor network pid 71
MYC Binding of TCF/LEF:CTNNB1 to target gene promoters reactome 7
MYC C-MYB transcription factor network pid 87
MYC C-MYC pathway pid 25
MYC CD40/CD40L signaling pid 36
MYC Ceramide signaling pathway pid 49
MYC Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants reactome 57
MYC Constitutive Signaling by NOTCH1 PEST Domain Mutants reactome 57
MYC Cyclin A:Cdk2-associated events at S phase entry reactome 15
MYC Cyclin E associated events during G1/S transition reactome 14
MYC E2F transcription factor network pid 77
MYC EGFR1 netpath 475
MYC Formation of the beta-catenin:TCF transactivating complex reactome 88
MYC FOXM1 transcription factor network pid 43
MYC IL2-mediated signaling events pid 54
MYC IL2 signaling events mediated by PI3K pid 38
MYC IL2 signaling events mediated by STAT5 pid 30
MYC IL6-mediated signaling events pid 48
MYC Interleukin signaling pathway panther 86
MYC LKB1 signaling events pid 43
MYC MAPK6/MAPK4 signaling reactome 90
MYC Notch signaling pathway pid 58
MYC NOTCH1 Intracellular Domain Regulates Transcription reactome 47
MYC Oxidative stress response panther 23
MYC p53 pathway feedback loops 2 panther 42
MYC p73 transcription factor network pid 80
MYC PDGF signaling pathway panther 113
MYC PDGFR-beta signaling pathway pid 125
MYC Presenilin action in Notch and Wnt signaling pid 46
MYC Prolactin netpath 105
MYC Regulation of nuclear beta catenin signaling and target gene transcription pid 80
MYC Regulation of nuclear SMAD2/3 signaling pid 82
MYC Regulation of Telomerase pid 70
MYC SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription reactome 32
MYC TGF_beta_Receptor netpath 220
MYC Validated nuclear estrogen receptor alpha network pid 65
MYC Validated targets of C-MYC transcriptional activation pid 80
MYC Validated targets of C-MYC transcriptional repression pid 63
MYC MAPK signaling pathway kegg 264
MYC ErbB signaling pathway kegg 83
MYC Cell cycle kegg 124
MYC Wnt signaling pathway kegg 135
MYC TGF-beta signaling pathway kegg 82
MYC Jak-STAT signaling pathway kegg 149
MYC Pathways in cancer kegg 321
MYC Colorectal cancer kegg 63
MYC Endometrial cancer kegg 52
MYC Thyroid cancer kegg 25
MYC Bladder cancer kegg 38
MYC Chronic myeloid leukemia kegg 69
MYC Acute myeloid leukemia kegg 53
MYC Small cell lung cancer kegg 83
MYC Hs_DNA_Damage_Response_(only_ATM_dependent)_WP710_79974 wikipathways 36
MYC Hs_TP53_Network_WP1742_71700 wikipathways 10
MYC Hs_Imatinib_and_Chronic_Myeloid_Leukemia_WP3640_89384 wikipathways 11
MYC Hs_miRNAs_involved_in_DNA_damage_response_WP1545_84697 wikipathways 30
MYC Hs_Association_Between_Physico-Chemical_Features_and_Toxicity_Associated_Pathways_WP3680_90113 wikipathways 31
MYC Hs_Gastric_Cancer_Network_2_WP2363_87523 wikipathways 28
MYC Hs_Hepatitis_C_and_Hepatocellular_Carcinoma_WP3646_88640 wikipathways 36
MYC Hs_Apoptosis_WP254_88977 wikipathways 31
MYC Hs_Integrated_Breast_Cancer_Pathway_WP1984_82941 wikipathways 122
MYC Hs_Neural_Crest_Differentiation_WP2064_79263 wikipathways 40
MYC Hs_IL-5_Signaling_Pathway_WP127_78498 wikipathways 35
MYC Hs_Prolactin_Signaling_Pathway_WP2037_90015 wikipathways 52
MYC Hs_EGF-EGFR_Signaling_Pathway_WP437_79266 wikipathways 107
MYC Hs_IL-7_Signaling_Pathway_WP205_89854 wikipathways 16

Enhancer associated network

The number on yellow line represents the distance between enhancer and target gene

Expression of target genes for the enhancer


Enhancer associated SNPs